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<b/> Colorectal cancer with BRAFV600E mutation can be effectively treated with combination approaches involving inhibition of BRAF, MEK, and EGFR proteins. However, activation of the MAPK pathway, often due to emergence of previously undetected molecular alterations, ultimately leads to adaptive therapeutic resistance. Novel combination strategies combining inhibition of BRAF, ERK, and EGFR can be used to prevent MAPK pathway-driven resistance and warrant further investigation. Cancer Discov; 8(4); 389-91. ©2018 AACRSee related article by Corcoran et al., p. 428See related article by Hazar-Rethinam et al., p. 417.